Clinical trials: Obstructive Pulmonary Diseases
Asthma
A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma
The research hypothesis for the proposed study asks the question, can Asmanex® demonstrate comparable anti-inflammatory therapeutic efficacy to the combination product, Advair® in control of mild persistent asthma? The purpose is…
- Trial name
- NCT00461812
- Testing
- Mometasone, Advair
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Johns Hopkins University
Pulmonary Disease, Chronic Obstructive
A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
To compare the persistence in using two different medications from the same drug class (LAMA/LABA FDC) which are delivered through different devices, a dry-powder inhalers (DPI) and Soft Mist Inhalers (SMI).
- Trial name
- NCT03979807
- Testing
- Olodaterol/Tiotropium Bromide, Umeclidinium/ Vilanterol
- Where
- United States
- Volunteers
- 11,296 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF)
Clinical Trials for Elderly Patients With Multiple Disease
The CHROMED project focuses its investigation on the applicability of an integrated solution for a pathological condition which: a) is very prevalent in ageing patients and b) severely impairs quality of life: COPD with other…
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), Sleep Disordered Breathing (SDB)
- Trial name
- CHROMED (NCT01960907)
- Testing
- CHROMED monitoring system
- Where
- 6 sites in Estonia, Slovenia and 3 more
- Volunteers
- 312 people
- Sponsor
- Restech Srl
Pulmonary Disease, Chronic Obstructive
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
The aim of this real world study is to assess the safety profile of tiotropium/olodaterol (Tio/Olo).
- Trial name
- NCT05393245
- Testing
- Tiotropium+Olodaterol, Spiolto Respimat, Long-acting muscarinic antagonists (LAMAs)
- Where
- China
- Volunteers
- 19,467 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in…
- Trial name
- NCT06261957
- Testing
- Salbutamol HFA-134a, Salbutamol HFA-152a
- Where
- 102 sites in United States, Argentina and 11 more
- Volunteers
- 471 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)
The objective of this study is to investigate the patient acceptability/preference of Respimat® compared with Handihaler® in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) to demonstrate the…
- Trial name
- NCT03964207
- Testing
- Tiotropium Respimat® (T1), Tiotropium Handihaler® (T2)
- Where
- 8 sites in China
- Volunteers
- 72 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, COPD
A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients
This study in Chronic Obstructive Pulmonary Disease (COPD) patients will investigate the bronchodilatory effect of AZD8683. AZD8683 will be tested versus placebo and an active comparator.
- Trial name
- NCT01708057
- Testing
- AZD8683, Tiotropium
- Where
- 6 sites in Poland, Sweden
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Asthma
A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma
Mepolizumab, a humanized monoclonal antibody, has been developed as an add-on treatment for subjects with severe asthma with eosinophilic inflammation.
- Trial name
- NCT03562195
- Testing
- Mepolizumab 100 milligrams, Salbutamol
- Where
- 42 sites in China
- Volunteers
- 300 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients
This is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, double dummy, 3-treatment, parallel study, with low and high YPL 001 doses (low dose and high dose twice daily [BID]) and a placebo control in moderate…
- Trial name
- NCT02272634
- Testing
- YPL-001 80 mg, YPL-001 160 mg
- Where
- 4 sites in United States
- Volunteers
- 61 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
Asthma
Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices
This study assessed the efficacy, safety, tolerability, and pharmacokinetics of two different formulations of indacaterol, one administered via the Concept1 device and one administered via the Simoon device.
- Trial name
- NCT01012739
- Testing
- Indacaterol 150 μg via the Concept1 dry-powder inhaler, Indacaterol 60 μg via the Simoon dry-powder inhaler, Indacaterol 120 μg via the Simoon dry-powder inhaler
- Where
- 4 sites in Germany, Netherlands and 1 more
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 μg and QVM149 150/50/160 μg via Concept1) over two respective QMF149 doses (QMF149 150/160 μg and QMF149 150/320)…
- Trial name
- NCT02571777
- Testing
- QVM149 150/50/160, QVM149 150/50/80, QMF149 150/320
- Where
- 403 sites in Argentina, Austria and 39 more
- Volunteers
- 3,092 people
- Sponsor
- Novartis Pharmaceuticals
COPD
A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.
- Trial name
- NCT02040792
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 355 people
- Sponsor
- Mylan Inc.
Asthma
Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations
The objective of this study is to determine whether, in children receiving low-dose inhaled corticosteroids (ICS), quintupling the dose of inhaled corticosteroids at the onset of symptoms previously associated with upper…
- Trial name
- STICS (NCT02066129)
- Testing
- Fluticasone 44 mcg, Fluticasone 220 mcg
- Where
- 18 sites in United States
- Volunteers
- 254 people
- Sponsor
- Milton S. Hershey Medical Center
Hepatitis C, Hepatocellular Carcinoma
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
The primary objective is to determine if the administration of a combination of sofosbuvir (SOF; GS-7977; PSI-7977) and ribavirin (RBV) to HCV-infected adults with hepatocellular carcinoma (HCC) meeting the MILAN criteria prior…
- Trial name
- NCT01559844
- Testing
- Sofosbuvir, Ribavirin
- Where
- 15 sites in United States, New Zealand and 1 more
- Volunteers
- 61 people
- Sponsor
- Gilead Sciences
Pulmonary Disease, Chronic Obstructive
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I
To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- NCT01040130
- Testing
- Olodaterol (BI 1744)
- Where
- 19 sites in Australia, Austria and 3 more
- Volunteers
- 151 people
- Sponsor
- Boehringer Ingelheim
CHF, COPD
A Technology Assisted Care Transition Intervention for Veterans With CHF or COPD
Transition from hospital to home places patients in jeopardy of adverse events and increases their risk for rehospitalization. CHF is the most prevalent chronic condition among U.S.
- Trial name
- TACT (NCT02632552)
- Testing
- Technology-assisted care transition intervention, Active attention control
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease
COPD Assessment and Management Bundle Versus Usual Care
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory (lung) disease that makes it harder to breathe over time.
- Trial name
- NCT01833026
- Testing
- Spirometry test, Levalbuterol
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- University of Illinois Chicago
Pulmonary Disease, Chronic Obstructive
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
The aim of this First Time in Patient study is to obtain initial information on the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of repeat daily administration of danirixin in subjects with…
- Trial name
- NCT02130193
- Testing
- Danirixin
- Where
- 16 sites in United States, Germany
- Volunteers
- 102 people
- Sponsor
- GlaxoSmithKline
COPD
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase [PDE]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT03443414
- Testing
- RPL554 suspension
- Where
- 49 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 405 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period.
- Trial name
- NCT00931385
- Testing
- BI 1744, bi1744, Foradil
- Where
- 11 sites in United States
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.